◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › B › BNTC

Benitec Biopharma Inc. (BNTC) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-10-03

Benitec Biopharma Inc. (BNTC) operates in the BIOTECHNOLOGY industry and is headquartered in Hayward, United States with about 24 employees. Its market capitalization is roughly $305 million. In the fiscal year ended 2026-06-30, BNTC reported $0M in revenue and ($46M) in net income.

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States.

Interactive charts & full statements →

BNTC Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2026-06-30	2025-06-30	2024-06-30	2023-06-30	2022-06-30	2021-06-30	2020-06-30	2019-06-30	2018-06-30	2017-06-30	2016-06-30	2015-06-30	2014-06-30	2013-06-30	2012-06-30	2011-06-30	2010-06-30	2009-06-30	2008-06-30	2007-06-30
Total Revenue	($1M)	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$17M	$4M	$0M	$0M	$1M	$1M	$1M	$0M	$0M	$0M	$0M	$0M	$0M
Gross Profit	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$16M	$4M	$0M	$0M	$1M	$1M	$0M	($1M)	($1M)	($1M)	($1M)	($2M)	($1M)
Gross Margin %	57.7%	—	—	-158.8%	100.0%	87.7%	-108.5%	290.7%	91.1%	89.7%	18.3%	70.0%	96.3%	96.3%	67.7%	-259.7%	-604.9%	-915.1%	-666.7%	-850.0%	-224.2%
Operating Income (EBIT)	($51M)	($51M)	($42M)	($22M)	($19M)	($18M)	($14M)	($8M)	$4M	($9M)	($16M)	($19M)	($10M)	($14M)	($8M)	($4M)	($3M)	($3M)	($2M)	($3M)	($1M)
Operating Margin %	6145.2%	—	—	-10412.0%	-25441.3%	-24457.5%	-23044.1%	-8537.1%	21.2%	-198.4%	-8132.4%	-7204.2%	-1607.6%	-1414.9%	-1494.9%	-1325.9%	-1992.6%	-1716.5%	-1148.2%	-1037.6%	-346.9%
Net Income	($46M)	($46M)	($38M)	($22M)	($20M)	($18M)	($14M)	($8M)	$4M	($12M)	($6M)	($14M)	($7M)	($7M)	($4M)	($4M)	($3M)	($5M)	($2M)	($3M)	($3M)
Net Margin %	5467.4%	—	—	-10069.9%	-26082.7%	-24942.5%	-23528.8%	-8529.9%	21.4%	-280.1%	-2860.4%	-5340.1%	-1064.7%	-718.2%	-766.8%	-1271.0%	-2255.8%	-3069.9%	-1055.5%	-965.5%	-682.3%
EBITDA	($51M)	($51M)	($41M)	($22M)	($19M)	($18M)	($13M)	($8M)	$2M	($6M)	($3M)	($21M)	($6M)	($10M)	($6M)	($4M)	($3M)	($3M)	($2M)	($3M)	($1M)
Earnings Per Share (EPS)	$-0.99	$-0.98	$-1.05	$-2.12	$-14.12	$-9.47	$-13.74	$-34.43	$18.51	$-74.68	$-40.72	$-123.69	$-74.10	$-96.82	$-218.18	$-110.41	$-156.95	$-255.85	$-149.51	$-180.62	$-240.98
Shares Outstanding (M)	47M	47M	36M	—	1M	2M	1M	0M	0M	0M	0M	0M	0M	0M	0M	0M	0M	0M	0M	0M	0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BNTC Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Total Revenue	($1M)	$0M	$0M	$0M	$1M	$0M	$0M	$0M
Gross Profit	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Gross Margin %	14.9%	—	—	—	50.0%	—	—	—
Operating Income (EBIT)	($14M)	($14M)	($13M)	($10M)	($10M)	($15M)	($11M)	($6M)
Operating Margin %	1732.2%	—	—	—	-1768.7%	—	—	—
Net Income	($13M)	($12M)	($12M)	($9M)	($16M)	($15M)	($10M)	($5M)
Net Margin %	1537.6%	—	—	—	-2904.1%	—	—	—
EBITDA	($14M)	($13M)	($13M)	($10M)	($17M)	($15M)	($11M)	($6M)
Earnings Per Share (EPS)	$-0.28	$-0.24	$-0.26	$-0.22	$-0.45	$-0.38	$-0.43	$-0.48
Shares Outstanding (M)	47M	49M	46M	42M	36M	39M	22M	11M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BNTC Free Cash Flow History

Cash flow	TTM → 2026-06-30	2026-06-30	2025-06-30	2024-06-30	2023-06-30	2022-06-30	2021-06-30	2020-06-30	2019-06-30	2018-06-30	2017-06-30	2016-06-30	2015-06-30	2014-06-30	2013-06-30	2012-06-30	2011-06-30	2010-06-30	2009-06-30	2008-06-30	2007-06-30
Cash from Operations (CFO)	($17M)	($17M)	($24M)	($19M)	($18M)	($16M)	($13M)	($8M)	$5M	($10M)	($8M)	($20M)	($10M)	($9M)	($3M)	($3M)	($3M)	($2M)	($2M)	($3M)	($2M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($17M)	($17M)	($24M)	($20M)	($18M)	($16M)	($13M)	($8M)	$4M	($10M)	($8M)	($20M)	($10M)	($10M)	($3M)	($3M)	($3M)	($2M)	($2M)	($3M)	($2M)
FCF Margin %	2050.8%	—	—	-9065.7%	-24017.3%	-21797.3%	-22123.7%	-7866.0%	25.1%	-224.0%	-4306.4%	-7915.6%	-1598.6%	-995.6%	-606.5%	-981.6%	-2045.5%	-1544.2%	-919.8%	-1077.8%	-473.0%
Dividends Paid	—	—	—	$1M	—	—	—	—	$0M	$0M	$0M	$0M	$0M	—	—	—	—	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BNTC Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30
Cash from Operations (CFO)	($5M)	($5M)	($4M)	($3M)	($9M)	($3M)	($8M)	($5M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($5M)	($5M)	($4M)	($3M)	($9M)	($3M)	($8M)	($5M)
FCF Margin %	602.4%	—	—	—	-1534.0%	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BNTC Balance Sheet History

Balance sheet	2026-06-30	2026-06-30	2025-06-30	2024-06-30	2023-06-30	2022-06-30	2021-06-30	2020-06-30	2019-06-30	2018-06-30	2017-06-30	2016-06-30	2015-06-30	2014-06-30	2013-06-30	2012-06-30	2011-06-30	2010-06-30	2009-06-30	2008-06-30	2007-06-30
Total Assets	$183M	$183M	$100M	$52M	$4M	$6M	$21M	$12M	$28M	$21M	$23M	$20M	$26M	$24M	$31M	$3M	$7M	$1M	$2M	$2M	$5M
Cash & Cash Equivalents	$180M	$180M	$98M	$51M	$2M	$4M	$20M	$10M	$22M	$16M	$17M	$18M	$22M	$21M	$29M	$3M	$7M	$0M	$0M	$0M	$5M
Total Liabilities	$6M	$6M	$2M	$5M	$4M	$3M	$1M	$2M	$3M	$3M	$1M	$1M	$1M	$2M	$1M	$1M	$2M	$2M	$1M	$1M	$2M
Total Debt (Short + Long-Term)	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Total Shareholders' Equity	$177M	$177M	$97M	$47M	$0M	$3M	$20M	$10M	$17M	$14M	$22M	$14M	$18M	$22M	$31M	$3M	$5M	($1M)	$1M	$1M	$4M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive BNTC viewer.

Other Companies in BIOTECHNOLOGY

AVIR · Atea Pharmaceuticals Inc — $330 million
ARCT · Arcturus Therapeutics Holdings Inc — $314 million
ENTA · Enanta Pharmaceuticals Inc — $312 million
PRLD · Prelude Therapeutics Inc — $309 million
VOGX · Vogenx Inc Common Stock — $301 million
SCTX · Scribe Therapeutics Inc. Common Stock — $292 million
EIKN · Eikon Therapeutics, Inc. Common Stock — $288 million
IPSC · Century Therapeutics Inc — $266 million

← BNT All “B” companies BNTX →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.